drugset / Trial / NCT06902467

Combined Intraperitoneal Chemotherapy Regimen After Optimal Interval Surgery in Advanced Ovarian Cancer: BICOV-1 (Bidirectional Chemotherapy in Ovarian Cancer)

NCT06902467

NaSingle-groupOpen-labelTreatment

Summary

A multicenter, low-intervention, drug-based study to evaluate the feasibility and safety of a combined regimen of two intraperitoneal chemotherapy modalities (used in routine clinical practice) following interval surgery for the treatment of advanced ovarian cancer. This is an independent research project (free of commercial interests).

Timeline

Start
2023-02-27
Primary completion
2026-03-15
Completion
2026-12-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified 100 mg/m2 Other
Subject Paclitaxel Small molecule 60 mg/m2 Other
Subject Paclitaxel Small molecule 175 mg/m2 Intravenous

Indications